Our Focus
Enabling earlier detection and improved monitoring of neurological disorders
Neurological disorders affect around one billion people globally, and an estimated 50% or more people suffer from multiple disorders.
With therapies that can slow the progression of Alzheimer’s disease entering the market, and more than 100 therapeutics currently being evaluated in clinical trials for neurological diseases, there is a growing need for accurate and timely diagnosis and monitoring for all patients.
Early detection of Alzheimer’s disease, Parkinson’s disease and other neurological disorders can improve the benefits of therapies and can empower proactive treatment and care decisions. Despite this need, there are limited blood tests available for Alzheimer’s disease and no blood tests available for other neurological diseases associated with dementia, including Parkinson’s disease.
By providing a comprehensive set of quantifiable diagnostics across the vast majority of neurological diseases, we can catalyze the transformation required to enable precision neurology, which may:
-
Accelerate drug development and increase the probability of more approved therapies
-
Facilitate earlier and more complete diagnoses of patients to allow for more targeted treatments
-
Provide the ability to easily monitor disease progression utilizing a simple blood test
Our blood-based diagnostic platform offers the potential to provide unprecedented insights to support earlier, more accurate diagnosis and treatment of Alzheimer's disease, Parkinson's disease and other neurological disorders.
